Clinical Trial Detail

NCT ID NCT03359239
Title Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Matthew Galsky
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Atezolizumab + PGV 001

Age Groups: adult senior

No variant requirements are available.